Bristol-Myers Squibb Co (NYSE:BMY) has announced that it will present over eighty abstracts from its oncology portfolio at the 51st Annual Meeting of the American Society of Hematology on December 5-8. The company will give two oral presentations featuring data on its SPRYCEL® on patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. An additional presentation will be held to present the data on elotuzumab, developed for patients with multiple myeloma.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Bristol-Myers Squibb Company is focused on the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceutical and nutritional products. The company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited in August of 2008. The company’s branded generics business was acquired by GlaxoSmithKline plc in July of 2009.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
